In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation with options such as CPX-351, and the role of stem cell transplantation. He also emphasized the importance of molecular profiling and the integration of targeted therapies, such as FLT3 inhibitors, in both initial and relapse settings.
Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his…
Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet…
The American Society of Hematology (ASH) has released 2020 guidelines for treating newly diagnosed acute myeloid leukemia (AML) in older adults. Specifically, the guidelines help patients and doctors…
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine…
Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Eytan Stein, MD, Memorial…
